Chronic hepatitis B and hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths. More than 80% of HCC cases are from the Asian and African continents, and more than 50% of cases are from mainland China. Approximately 350 million to 400 million persons are chronically infected with hepatitis B virus (HBV), and this virus is the most common cause of HCC worldwide. It is estimated that more than 50% of liver cancers worldwide are attributable to HBV and up to 89% of HBV-related HCC are from developing countries. Recently, increasing trends in HCC incidence have been reported from several Western countries, including France, Australia, and the United States.
McClune
Amy C
AC
Dumont-UCLA Liver Transplant Center, David Geffen School of Medicine at UCLA, The Pfleger Liver Institute, Los Angeles, CA 90095-7302, USA. amcclune@mednet.ucla.edu
Tong
Myron J
MJ
D000367:Age Factors; D000998:Antiviral Agents / Q000627:therapeutic use; D001315:Australia; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D002681:China; D005602:France; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D016031:Liver Transplantation; D012307:Risk Factors; D012737:Sex Factors; D014481:United States
D000998:Antiviral Agents